Project Grant R01HL179167
Award Date 7/1/26
Completion Date 12/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
- Federal Grant Award Summary The University of Utah's Office of Sponsored Projects received a $470,606 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2026 through January 31, 2031. This award funds research to elucidate the molecular mechanisms by which smoking-induced endothelial dysfunction occurs in individuals carrying the ALDH2*2 genetic variant, a polymorphism affecting approximately...
- Federal Grant Award Summary The University of Utah received a $183,600 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 19, 2025, with completion by August 31, 2027. The award funds research investigating metabolite transport modulation to mitigate myocardial ischemic-reperfusion (I/R) injury, a cardiac injury mechanism that occurs during standard heart attack treatment protocols...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham a Project Grant of $535,556 under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for May 31, 2030. This award supports research to elucidate the role of a novel mechanosensitive histone modification (H3T32 O-GlcNAc) in atherosclerosis pathogenesis. The research investigates how atheroprone shear stress...
- Federal Grant Award Summary The University of Utah received a $654,530 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through July 31, 2029. This research project investigates the role of serum glucocorticoid kinase 1 (SGK1) in cardiometabolic heart failure with preserved ejection fraction (HFPEF), addressing a critical unmet medical need affecting approximately 33 million...
- Federal Grant Award Summary The University of Utah received a $231,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026, through May 31, 2028. This award funds research investigating the role of lung megakaryocytes and megakaryocyte-derived platelets in lung injury, with particular emphasis on immunothrombosis as a contributor to acute respiratory distress syndrome (ARDS) and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $676,459 to the University of Arizona on September 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of hexokinase 3 (HK3) in macrophage polarization and cardiac remodeling following myocardial infarction. The research project, extending through June 30, 2029, will generate scientific knowledge regarding how HK3 deletion enhances macrophage repair phenotypes...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $745,663 to the University of Utah under the Cardiovascular Diseases Research program (CFDA 93.837) for a project grant effective September 1, 2025, through June 30, 2029. The project, "Novel Roles for IRE1 in Regulating Cardiac Fibrosis," investigates mechanistic contributions of the unfolded protein response (UPR)—specifically the IRE1 (inositol-requiring enzyme 1) pathway—in regulating cardiac...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Utah a Project Grant totaling $740,709 under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with completion targeted for May 31, 2029. This research initiative focuses on defining cellular and molecular mechanisms by which early-life viral-induced inflammation drives asthma susceptibility through the reprogramming of type 2 innate lymphoid cells...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $1,529,105 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 25, 2025, with completion expected by May 31, 2029. This research grant funds investigation into the regulation of endothelial cell scavenger receptor class B type I (SR-BI) and its protein partners in atherosclerosis pathogenesis....
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded the University of Utah $400,976 on June 27, 2025, to conduct research investigating the role of pyruvate metabolic fate and lactate export in myofibroblast differentiation within myelofibrosis. The project, extending through January 31, 2028, will deliver mechanistic research findings on how blocking monocarboxylate transporter 4...